
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is expected to show strong revenue growth over the next few years, aided by their innovative product, the iLet Bionic Pancreas. The company has consistently beat estimates since going public in 2024, and we forecast continued growth in both revenue and gross margin. Despite recent challenges regarding FDA compliance, we believe their pipeline and potential market share gains make Beta Bionics a strong investment opportunity at current levels.
Bears say
Beta Bionics is facing operational risk due to a recent FDA warning letter, as well as a decline in NPS sales and a slower than expected commercialization timeline for their patch product. The company's positive gross margin lift and cash on hand may not be enough to offset these concerns and the company's dependence on the PBP channel may also limit growth potential. As a result, the negative outlook on Beta Bionics stock is justified.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares